Clinical Trial

Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

Study acronym: SEARCH
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is single - arm study to explore the safety and efficacy of iparomlimab and tuvonralimab (QL1706) combined with chemotherapy for treating her2-negative, low PD-L1 expressing, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-16.
Trial Details
NCT Number NCT06932068
Lead Sponsor Qilu Hospital of Shandong University
Conditions HER2 Negative, Low PD-L1 Expressing, Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Enrollment 77 participants
Start Date 2025-03-26
Primary Completion 2026-10-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-07